{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:58:31Z","timestamp":1781089111531,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.clml.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T18:13:59Z","timestamp":1417803239000},"page":"S78-S86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S","title":["Asymptomatic Monoclonal Gammopathies"],"prefix":"10.1016","volume":"14","author":[{"given":"Claire","family":"Bories","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.05.004_bib1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2014.05.004_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.05.004_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.521","article-title":"Localized and indolent myeloma","volume":"56","author":"Alexanian","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.05.004_bib5","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib6","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.05.004_bib7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.05.004_bib8","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.05.004_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosi\u00f1ol","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.05.004_bib10","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","article-title":"Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence","volume":"85","author":"Rajkumar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2014.05.004_bib12","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.05.004_bib13","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib15","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A\u00a0long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.05.004_bib17","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib18","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.05.004_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"P\u00e9rez-Persona","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.05.004_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/leu.2013.244","article-title":"Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance","volume":"28","author":"Hillengass","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib21","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.05.004_bib22","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.05.004_bib24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1365-2141.1999.01244.x","article-title":"Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma","volume":"104","author":"Mariette","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.05.004_bib26","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","article-title":"Solitary plasmacytoma of bone and asymptomatic multiple myeloma","volume":"96","author":"Dimopoulos","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","article-title":"Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"13","author":"Moulopoulos","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.05.004_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","article-title":"Prognostic features of asymptomatic multiple myeloma","volume":"97","author":"Weber","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.05.004_bib29","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.05.004_bib30","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib32","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.05.004_bib33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib34","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.1996.212","article-title":"A\u00a0prognostic index for multiple myeloma","volume":"73","author":"Grignani","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2014.05.004_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.05.004_bib36","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2014.05.004_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A\u00a0phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.05.004_bib39","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.05.004_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.05.004_bib41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.21821","article-title":"Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma","volume":"85","author":"Detweiler-Short","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.05.004_bib42","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.05.004_bib43","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A\u00a0multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.05.004_bib44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"Mart\u00edn","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.05.004_bib45","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D'Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.05.004_bib46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1\u03b2-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2014.05.004_bib47","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.23159","article-title":"Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study","volume":"87","author":"Golombick","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.05.004_bib48","doi-asserted-by":"crossref","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, et al. Initial Phase 3 results of the First (Frontline Investigation of Lenalidomide + Dexamethasone versus Standard Thalidomide) trial (MM-020\/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT). Proc ASH 2013; abstract 2.","DOI":"10.1182\/blood.V122.21.2.2"},{"key":"10.1016\/j.clml.2014.05.004_bib49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2014.05.004_bib50","doi-asserted-by":"crossref","unstructured":"Landgren O, Mailankody S, Kwok M, et al. Clinical and correlative pilot study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRd \u2013 R) in high risk smoldering multiple myeloma patients. Proc ASH 2013; abstract 1939.","DOI":"10.1182\/blood.V122.21.1939.1939"},{"key":"10.1016\/j.clml.2014.05.004_bib51","doi-asserted-by":"crossref","unstructured":"Korde N, Zingone A, Kwok ML, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients. Proc ASH 2013; abstract 538.","DOI":"10.1182\/blood.V122.21.538.538"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:44Z","timestamp":1761870344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":51,"alternative-id":["S2152265014001694"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.05.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asymptomatic Monoclonal Gammopathies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}